Press coverage about Albireo Pharma (NASDAQ:ALBO) has been trending somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Albireo Pharma earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.141956684355 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
ALBO has been the topic of a number of analyst reports. Needham & Company LLC lifted their price objective on Albireo Pharma to $50.00 and gave the company a “buy” rating in a report on Friday, February 2nd. Roth Capital started coverage on shares of Albireo Pharma in a research report on Wednesday, November 15th. They set a “buy” rating and a $92.00 price target for the company. ValuEngine upgraded shares of Albireo Pharma from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Cowen reiterated a “buy” rating on shares of Albireo Pharma in a research report on Friday, November 17th. Finally, Wedbush reiterated a “buy” rating on shares of Albireo Pharma in a research report on Friday, January 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Albireo Pharma currently has an average rating of “Hold” and a consensus price target of $58.25.
Shares of Albireo Pharma (NASDAQ ALBO) opened at $35.33 on Wednesday. Albireo Pharma has a 12-month low of $15.31 and a 12-month high of $39.87.
About Albireo Pharma
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.